Name: 275: A thorny ALS debate at the FDA, and the promise of artificial wombs by STAT
Duration: 33 min 3 s
Description: Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consider the thorny case of a potential medicine for ALS whose supporting evidence has polarized patients and physicians.

This week is a special two-part episode focusing on last week’s controversial — some say inflammatory — decision to approve aducanumab, a new Alzheimer’s drug. In these episodes, I talk with two Alzheimer’s experts with vastly different viewpoints on the news. First up: Dennis J. Selkoe, a physician and scientist whose research is at the core of how Aduhelm works.

Episode 19, Part 1: An original believer on the aducanumab decision

Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consider the thorny case of a potential medicine for ALS whose supporting evidence has polarized patients and physicians.

275: A thorny ALS debate at the FDA, and the promise of artificial wombs

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

275: A thorny ALS debate at the FDA, and the promise of artificial wombs

STAT

Related tracks